1. Home
  2. GANX

GANX

Gain Therapeutics Inc.

Logo Gain Therapeutics Inc.

Health Care

Biotechnology: Pharmaceutical Preparations

Nasdaq

as 04-18-2024 3:20pm EST

$
-
.
-
-
+$
-
.
-
-
+
-
.
-
-
%

Gain Therapeutics Inc is a biotechnology company developing novel small molecule therapeutics to treat diseases across, several therapeutics areas, including, lysosomal storage disorders, central nervous system disorders, metabolic disorders, and oncology. The company's clinical-stage product candidate, GT-02287, is being developed for the treatment of GBA1 Parkinson's disease. The company uses its computational target and drug discovery platform, Magellan, to discover novel allosteric binding sites on proteins implicated in disease and to identify proprietary small molecules that bind these sites to modulate protein function and treat the underlying cause of the disease. The company derives revenues from collaboration and licensing agreements.

Founded: 2017 Country:
United States
United States
Employees: N/A City: BETHESDA
Market Cap: 57.7M IPO Year: 2021
Target Price: $8.75 AVG Volume (30 days): 160.7K
Analyst Decision: Strong Buy Number of Analysts: 4
Dividend Yield: N/A Dividend Payout Frequency: N/A
EPS: -1.71 EPS Growth: N/A
52 Week Low/High: $2.00 - $6.19 Next Earning Date: 05-10-2024
Revenue: $55,180 Revenue Growth: -60.62%
Revenue Growth (this year): 2025.77% Revenue Growth (next year): -65.22%

Share on Social Networks: